Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 26;6(4):00032-2020.
doi: 10.1183/23120541.00032-2020. eCollection 2020 Oct.

Gender does not impact the short- or long-term outcomes of home-based pulmonary rehabilitation in patients with COPD

Affiliations

Gender does not impact the short- or long-term outcomes of home-based pulmonary rehabilitation in patients with COPD

Jean-Marie Grosbois et al. ERJ Open Res. .

Abstract

Pulmonary rehabilitation, whether performed at home or in a specialised centre, is effective in the management of COPD. As gender-related differences in COPD were previously reported, we aimed to evaluate the impact of gender on pulmonary rehabilitation outcomes in the short, medium and long term. In this retrospective observational study of 170 women and 310 men with COPD, we compared the outcomes of an 8-week home-based pulmonary rehabilitation programme including an individualised plan of retraining exercises, physical activities, therapeutic education, and psychosocial and self-management support. Exercise tolerance, anxiety, depression, and quality of life (QOL) were assessed using the 6-min stepper test (6MST), Hospital Anxiety and Depression Scale (HADS) and Visual Simplified Respiratory Questionnaire (VSRQ), respectively. Assessments were carried out before, immediately after the pulmonary rehabilitation programme (T2) and at 8 (T8) and 14 months (T14). At baseline, women were younger (mean 62.1 versus 65.3 years), more often nonsmokers (24.7% versus 7.7%) and had a higher body mass index (28 versus 26.4 kg·m-2). They more often lived alone (50.6% versus 24.5%) and experienced social deprivation (66.7% versus 56.4%). They had significantly lower exercise tolerance (-34 strokes, 6MST) and higher anxiety and depression (+3.2 HADS total score), but there were no between gender differences in QOL (VSRQ). Both groups showed similar improvements in all outcome measures at T2, T8 and T14 with a tendency for men to lose QOL profits over time. Despite some differences in baseline characteristics, women and men with COPD had similar short-, medium- and long-term benefits of a home-based pulmonary rehabilitation programme.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J-M. Grosbois reports FormAction Santé (J-M. Grosbois) received financial support from Adair, Aeris Santé, Bastide, France Oxygène, Homeperf, LVL Medical, Medopale, NorOx, Santélys, Santeo, SOS Oxygène, Sysmed, VitalAire and the ARS Hauts de France for the home-based pulmonary rehabilitation programme; personal fees and nonfinancial support from AstraZeneca and Boehringer Ingelheim, personal fees from Chiesi, nonfinancial support from GlaxoSmithKline and Novartis, and personal fees from Vitalaire and Roche, during the conduct of the study. Conflict of interest: S. Gephine has nothing to disclose. Conflict of interest: A.S. Diot has nothing to disclose. Conflict of interest: M. Kyheng has nothing to disclose. Conflict of interest: F. Machuron has nothing to disclose. Conflict of interest: G. Terce has nothing to disclose. Conflict of interest: B. Wallaert reports personal fees and nonfinancial support from Roche and Boehringer Ingelheim, and nonfinancial support from Vitalaire, outside the submitted work. Conflict of interest: C. Chenivesse reports grants from AstraZeneca and Santélys, personal fees from ALK-Abello, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Roche, Sanofi and TEVA, and nonfinancial support from ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MEDA Pharma, Medexact, Novartis, Pierre Fabre and Pfizer, outside the submitted work. Conflict of interest: O. Le Rouzic reports personal fees and nonfinancial support from AstraZeneca, Boehringer Ingelheim, Chiesi, Lilly and Novartis, and nonfinancial support from GlaxoSmithKline, MundiPharma, Pfizer, Teva, Santelys Association, Vertex and Vitalaire, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Flow chart.
FIGURE 2
FIGURE 2
Changes in exercise tolerance, quality of life, anxiety and depression in COPD patients according to gender. (a–d) Changes in parameters from T0 (baseline) to T2, T8 and T14 (2, 8 and 14 months after T0) for (a) Hospital Anxiety and Depression Scale (HADS) anxiety subscore, (b) HADS-depression subscore, (c) 6-min stepper test (6MST) stroke number and (d) Visual Simplified Respiratory Questionnaire (VSRQ) score. Data are presented as the mean±sem at each time for the whole population. p-values are adjusted for baseline value of age, body mass index, living arrangement, smoking status, forced expiratory volume in 1 s (FEV1) (% pred), EPICES (Evaluation of Deprivation and Inequalities in Health Centres) score, and coronary artery disease or peripheral vascular disease. p-value is the Pinteraction for the interaction between time and group (i.e. <0.05 indicates a significant difference in the change in variable with time compared between the two patient groups). All analyses were adjusted to the baseline value. Minimum–maximum scores: HADS total, 0–42; HADS subscores, 0–21 (low to high anxiety/depression); VSRQ, 0–80 (low to high quality of life).
FIGURE 3
FIGURE 3
Percentage of patients who responded to pulmonary rehabilitation according to gender. Data are presented as the percentage of patients who responded to pulmonary rehabilitation, with response defined as a change of ≥MCID for the indicated assessments at 2 (T2), 8 (T8) and 14 (T14) months compared with the start of the pulmonary rehabilitation programme. 6MST: number of strokes in the 6-min stepper test; MCID: minimum clinically important difference; VSRQ: Visual Simplified Respiratory Questionnaire. *: p<0.05.

Similar articles

Cited by

References

    1. Aryal S, Diaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. Int J Chron Obstruct Pulmon Dis 2014; 9: 1145–1154. - PMC - PubMed
    1. Gut-Gobert C, Cavaillès A, Dixmier A, et al. . Women and COPD: do we need more evidence? Eur Respir Rev 2019; 28: 180055. doi:10.1183/16000617.0055-2018 - DOI - PMC - PubMed
    1. Martinez CH, Raparla S, Plauschinat CA, et al. . Gender differences in symptoms and care delivery for chronic obstructive pulmonary disease. J Womens Health 2012; 21: 1267–1274. doi:10.1089/jwh.2012.3650 - DOI - PMC - PubMed
    1. Ni H, Xu J. COPD-related mortality by sex and race among adults aged 25 and over: United States, 2000–2014. NCHS Data Brief 2016; 256: 1–8. - PubMed
    1. Spruit MA, Singh SJ, Garvey C, et al. . An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13–e64. doi:10.1164/rccm.201309-1634ST - DOI - PubMed

LinkOut - more resources